Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 4:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,653 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Schizophrenia Spectrum Disorders Clear all
Completed Phase 2 Interventional

Effects of Atomoxetine on Cognitive Function in Schizophrenia

NCT00420498
View directory record Official record
Conditions
Schizophrenia, Cognition, Smoking
Interventions
Atomoxetine (Strattera™)
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 59 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 11, 2007 · Synced Sep 4, 2026, 4:10 AM EDT
Completed Not applicable Interventional Results available

Transcranial Current Stimulation as a Treatment for Auditory Hallucinations in Schizophrenia

NCT01963676
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Auditory Hallucinations
Interventions
tDCS, Sham stimulation
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 21, 2016 · Synced Sep 4, 2026, 4:10 AM EDT
Completed Not applicable Interventional

Lifestyle Modification for Weight Loss in Schizophrenia

NCT00990925
View directory record Official record
Conditions
Obesity, Schizophrenia, Schizoaffective Disorder
Interventions
Nutritional Lifestyle Modification Group, Usual Care
Behavioral · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 4, 2015 · Synced Sep 4, 2026, 4:10 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations

NCT04296604
View directory record Official record
Conditions
Traumatic Brain Injury, Major Depressive Disorder, Bipolar Disorder, Schizophrenia, Attention Deficit Hyperactivity Disorder, Borderline Personality Disorder, Substance Use Disorders
Interventions
Transcranial Direct Current Stimulation
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Sep 4, 2026, 4:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics of Single Doses of APN1125 in Healthy Normal Subjects

NCT02331433
View directory record Official record
Conditions
Schizophrenia
Interventions
APN1125, Placebo
Drug
Lead sponsor
CoMentis
Industry
Eligibility
18 Years to 65 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Apr 7, 2016 · Synced Sep 4, 2026, 4:10 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effect of N-Acetyl Cysteine on Cortical Erosion in Early Stage Schizophrenia

NCT01339858
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorder NOS, Schizoaffective Disorder, Schizophreniform
Interventions
N-Acetyl Cysteine, sugar pill
Drug · Other
Lead sponsor
Indiana University
Other
Eligibility
16 Years to 35 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Sep 4, 2026, 4:10 AM EDT
Completed Not applicable Interventional

Improving Representative Payeeship for People With Psychiatric Disabilities and Their Families

NCT00924976
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder, Major Depressive Disorder
Interventions
Steps for Achieving Financial Empowerment (SAFE)
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Sep 4, 2026, 4:10 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Feasibility of an Early Detection Program for Early Psychosis on a College Campus

NCT03983421
View directory record Official record
Conditions
Psychosis, First Episode Psychosis, Clinical High Risk for Psychosis
Interventions
Not listed
Lead sponsor
University of New Mexico
Other
Eligibility
15 Years to 30 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 31, 2024 · Synced Sep 4, 2026, 4:10 AM EDT
Completed No phase listed Observational

Game-based Telehealth Therapeutic Intervention in First Onset Psychosis

NCT04799717
View directory record Official record
Conditions
Psychotic Disorders, Schizophrenia Spectrum Disorders
Interventions
Gaming session
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
10 Years to 18 Years
Enrollment
8 participants
Timeline
2021 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jan 8, 2023 · Synced Sep 4, 2026, 4:10 AM EDT
Completed Phase 2 Interventional Results available

A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder

NCT02161718
View directory record Official record
Conditions
Schizophrenia, Alcohol Use Disorder
Interventions
Samidorphan + olanzapine (ALKS 3831), Placebo + olanzapine
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
58
States / cities
Little Rock, Arkansas • Springdale, Arkansas • Anaheim, California + 50 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2021 · Synced Sep 4, 2026, 4:10 AM EDT
Completed Phase 2 Interventional Results available

This Study Tests Whether BI 425809 Together With Brain Training Using a Computer Improves Mental Functioning in Patients With Schizophrenia

NCT03859973
View directory record Official record
Conditions
Schizophrenia
Interventions
BI 425809, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 50 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
28
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Encino, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Sep 4, 2026, 4:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Test the Effects of Other Drugs on SEP-380135 in Healthy Men and Women

NCT07305779
View directory record Official record
Conditions
Schizophrenia
Interventions
SEP-380135, Quinidine Gluconate
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Sep 4, 2026, 4:10 AM EDT
Completed Not applicable Interventional Results available

Patient-Centered Medication Adherence Intervention for Schizophrenia

NCT00144027
View directory record Official record
Conditions
Schizophrenia
Interventions
Antipsychotic medication adherence intervention
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 70 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
No. Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2015 · Synced Sep 4, 2026, 4:10 AM EDT
Completed Not applicable Interventional

Adaptation of Cognitive Enhancement Therapy for Persons at Clinical High Risk for Psychosis

NCT02459210
View directory record Official record
Conditions
Psychosis
Interventions
CLUES, therapy and computer games
Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
16 Years to 25 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced Sep 4, 2026, 4:10 AM EDT
Completed Not applicable Interventional Results available

Building Employment Skills Through Therapy for Veterans

NCT01992913
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
integrated Cognitive Behavioral Therapy, Usual Care, Computerized cognitive remediation (CCR)
Behavioral · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 21, 2025 · Synced Sep 4, 2026, 4:10 AM EDT
Completed Not applicable Interventional

Creating Live Interactions to Mitigate Barriers

NCT03317769
View directory record Official record
Conditions
Schizophrenia
Interventions
Computerized Plasticity-Based Adaptive Cognitive Training, Commercially available computerized training, Optimized social skills training, Unstructured support group sessions
Other
Lead sponsor
Posit Science Corporation
Industry
Eligibility
18 Years to 60 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Sep 4, 2026, 4:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Point-of-Care Testing (POCT) Detection and Management of Metabolic Syndrome in Patients With Mental Illness

NCT02029989
View directory record Official record
Conditions
Hyperlipidemia, Diabetes, Hypertension
Interventions
Glucose and lipids, Glycosylated Hemoglobin A1c, Blood Pressure and Heart Rate, Body mass index, Waist and Hip circumference, Comprehensive Medication Management
Device · Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 64 Years
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Duluth, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Sep 4, 2026, 4:10 AM EDT
Completed Phase 2 Interventional Results available

Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation

NCT00167310
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Major Depression, Bipolar Disorder, Coronary Artery Disease
Interventions
Eicosapentaenoic acid (omega-3 fatty acid), Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 9, 2017 · Synced Sep 4, 2026, 4:10 AM EDT
Completed Phase 1 Interventional

Pharmacokinetics, Safety, and Tolerability of Lumateperone Long-Acting Injectable in Patients With Schizophrenia

NCT04709224
View directory record Official record
Conditions
Schizophrenia
Interventions
Lumateperone Long-Acting Injectable
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Long Beach, California • Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 4, 2022 · Synced Sep 4, 2026, 4:10 AM EDT
Completed Phase 2 Interventional Results available

RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder

NCT01490086
View directory record Official record
Conditions
Acute Schizophrenia, Schizoaffective Disorder
Interventions
RP5063, placebo, aripiprazole
Drug
Lead sponsor
Reviva Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Sep 4, 2026, 4:10 AM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy of PEAR-004 in Schizophrenia

NCT03751280
View directory record Official record
Conditions
Schizophrenia
Interventions
PEAR-004, Sham
Device
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
6
States / cities
Garden Grove, California • Oakland, California • Torrance, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Sep 4, 2026, 4:10 AM EDT
Completed Not applicable Interventional Results available

Theta Burst Stimulation for Schizophrenia

NCT03288779
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Theta Burst Stimulation
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Sep 4, 2026, 4:10 AM EDT
Completed Not applicable Interventional Results available

The Efficacy of Neural Stimulation in Individuals With Schizophrenia

NCT05746494
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder
Interventions
tDCS
Device
Lead sponsor
The University of Texas at Dallas
Other
Eligibility
18 Years to 64 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Sep 4, 2026, 4:10 AM EDT